Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) is a hospital affiliated with and operated by the United States Department of Veterans Affairs in the Texas Medical Center in Houston, Texas. It is one of the department's largest hospitals, serving Harris County, Texas and 27 surrounding counties. It is named for Michael E. DeBakey, a renowned surgeon and president of Baylor College of Medicine. The hospital is on a 118-acre (48 ha) campus on Old Spanish Trail and Almeda, just on the edge of the Texas Medical Center. It is accredited by JCAHO, and has 343 hospital beds, a 40-bed Spinal Cord Injury Center, and a 120-bed transitional care unit for long-term care. The hospital is staffed by Baylor College of Medicine and The University of Texas Health Science Center at Houston faculty, residents, and students. Baylor College of Medicine has been affiliated with the hospital since 1949. The facility also takes students and residents from the University of Texas at Austin College of Pharmacy.
BACKGROUND:These recommendations provide guidance on the optimal duration of antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia. METHODS:The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of shorter (5-7 days) vs prolonged (10-14 days) duration of antibiotics, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. RESULTS:The guidelines panel suggests that patients with cUTI who are improving on effective therapy can be treated with shorter duration of antimicrobials (either 5-7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone) rather than longer courses of antibiotics, regardless of the presence of associated Gram-negative bacteremia. An effective antimicrobial agent achieves therapeutic levels in the urine and relevant tissue and is active against the causative pathogen. However, men with febrile UTI in whom acute bacterial prostatitis is suspected may benefit from a longer treatment duration (10-14 days), and a short courses of oral beta lactams may require higher doses for efficacy. CONCLUSIONS:Shorter durations of antibiotics for cUTI provide similar efficacy as longer courses, except in men with febrile UTI in whom acute bacterial prostatitis is suspected. This recommendation places a high value on antibiotic stewardship considerations as well as reducing the burden of antimicrobial administration from a healthcare perspective and reducing the burden of taking antibiotics from a patient perspective.
Objectives To assess the construct validity of a modified single-item measure of bother due to side effects (the GP5 item) from the Functional Assessment of Chronic Illness Therapy (FACIT) system by comparing it to current symptomatic side effects from the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) reported by patients with rheumatoid arthritis (RA). Methods Through a cross-sectional, web-based survey we collected information on the frequency of symptomatic side effects and bother from side effects related to RA medications. We applied multiple correspondence analysis (MCA) to reduce 80 symptomatic side effects into key dimensions (≥5% of the total variance each). We then examined associations among key dimensions, individual items, the sum of current side effects, and the single-item bother measure using Spearman rho. Results A total of 560 patients participated in the online survey. Our scree plot showed a clear elbow point after the first dimension, indicating that keeping just one dimension captured the most meaningful information. This overall side effect burden score appeared to reflect a broad concept influenced by a variety of symptomatic side effects, each having only a negligible to weak impact. Conclusions Our results may indicate that individuals have diverse experiences of side effects, allowing the global index to capture these variations, even when they differ across patients. Thus, a single-item burden measure to side effects can potentially serve as a useful summary indicator, shedding light on the impact of symptomatic side effects experienced by RA patients.
This study examined the association of insomnia, sleep apnea, and comorbid insomnia and sleep apnea (COMISA) with all-cause mortality in a large Veteran sleep clinic cohort. We retrospectively identified Veterans with insomnia and/or SA using ICD-9/10 codes, requiring two diagnoses within 13 months (≥ 30 days apart). Insomnia cases also required relevant prescriptions and/or cognitive behavioral therapy for insomnia (CBT-I); SA cases required positive airway pressure prescriptions within three years. Patients were classified as insomnia only (INS), SA only, or COMISA. Adjusted odds ratios (aOR) for mortality were estimated using SA as the reference. Model 1 adjusted for age, sex, race, ethnicity, and Charlson Comorbidity Index (CCI); Model 2 additionally adjusted for trazodone and quetiapine; Model 3 additionally adjusted for benzodiazepines and benzodiazepine receptor agonists. Model 4 included all Model 3 covariates plus CBT-I. Among the 1,720,090 patients, 47.6
Transcatheter aortic valve replacement (TAVR) has created a growing population of patients who require redo-TAVR (TAV-in-TAV) for structural valve deterioration. Short-frame balloon-expandable valves implanted within failed short- or tall-frame transcatheter valves ("short-in-short" and "short-in-tall") pose specific challenges, including coronary risk assessment, valve sizing, anchoring, and preservation of coronary access. Under the auspices of the Heart and Valve Collaboratory, an international multidisciplinary panel of experts reviewed bench and clinical data and synthesized contemporary best practices into a pragmatic workflow for redo-TAVR. This document standardizes key anatomic definitions, outlines computed tomography-based strategies for in vivo sizing, and details recommended approaches to predilatation, deployment techniques, and postdilatation. By harmonizing terminology and stepwise planning across imaging, interventional, and surgical teams, this document aims to simplify procedural decision-making and improve safety, coronary preservation, and hemodynamic outcomes in patients undergoing short-in-short and short-in-tall TAV-in-TAV procedures.
PURPOSE:The Veteran Affairs (VA) New Jersey Parkinson's Disease (PD) Telepsychotherapy Hub (PD Telepsych Hub) delivers virtual mental health treatments to underserved rural Veterans in partnership with VA Parkinson's Disease Research, Education, and Clinical Centers (PADRECCs). This manuscript outlines the PD Telepsych Hub's hybrid type 2 implementation-effectiveness framework then presents the clinical and demographic characteristics of Enrolled Veterans along with mental health outcomes for Treatment Engagers receiving individual Cognitive Behavioral Therapy (CBT-PD) or group Mindfulness-Based Cognitive Therapy (MBCT-PD) over the first 5 years of operation (10/2020 to 09/2025). METHODS:Underserved rural Veterans with PD were primarily directly outreached by the PD Telepsych Hub (64%) or referred by VA clinicians. Veterans who met screening criteria and completed a psychiatric consult were enrolled and offered CBT-PD or MBCT-PD via telehealth according to preferences and needs. Enrolled Veterans completed baseline questionnaires assessing demographics and health characteristics. Treatment Engagers completed pre-and-post measures of mood, anxiety, loneliness, functional change, and treatment satisfaction. RESULTS:Enrolled Veterans (N = 522 across 31 states) were rural (72%), 6% Hispanic, 8% people of color, and on average 71-years-old. They reported an average of 7 years since PD diagnosis. Although most met criteria for a mood disorder (86%) and 43% had psychiatric comorbidities, only 9% were receiving psychotherapy at time of program enrollment. CBT-PD (n = 202) significantly reduced depression and anxiety, while MCBT-PD (n = 38) reduced depression. Treatment Engagers (n = 240) overall reported high treatment satisfaction (94%). CONCLUSION:At baseline, the mismatch between care access and clinical need was striking. Results highlight a growing foundation for real-world effectiveness in delivering empirically supported, PD-adapted interventions via telehealth to the highest-need, lowest-access populations.